- Home
- CUE vs ICCM Comparison
CUE vs ICCM Comparison
Compare CUE & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- ICCM
- Stock Information
- Founded
- CUE 2014
- ICCM 2006
- Country
- CUE United States
- ICCM Israel
- Employees
- CUE N/A
- ICCM N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- ICCM
- Sector
- CUE Health Care
- ICCM
- Exchange
- CUE Nasdaq
- ICCM Nasdaq
- Market Cap
- CUE 61.1M
- ICCM 57.5M
- IPO Year
- CUE 2018
- ICCM N/A
- Fundamental
- Price
- CUE $0.70
- ICCM $0.71
- Analyst Decision
- CUE Strong Buy
- ICCM Strong Buy
- Analyst Count
- CUE 2
- ICCM 1
- Target Price
- CUE $3.00
- ICCM $2.50
- AVG Volume (30 Days)
- CUE 270.3K
- ICCM 2.3M
- Earning Date
- CUE 11-12-2025
- ICCM 11-25-2025
- Dividend Yield
- CUE N/A
- ICCM N/A
- EPS Growth
- CUE N/A
- ICCM N/A
- EPS
- CUE N/A
- ICCM N/A
- Revenue
- CUE $8,286,000.00
- ICCM $2,787,000.00
- Revenue This Year
- CUE N/A
- ICCM $2.92
- Revenue Next Year
- CUE N/A
- ICCM $57.81
- P/E Ratio
- CUE N/A
- ICCM N/A
- Revenue Growth
- CUE N/A
- ICCM N/A
- 52 Week Low
- CUE $0.54
- ICCM $0.53
- 52 Week High
- CUE $1.99
- ICCM $1.66
- Technical
- Relative Strength Index (RSI)
- CUE 38.97
- ICCM 25.29
- Support Level
- CUE $0.76
- ICCM $0.79
- Resistance Level
- CUE $0.81
- ICCM $0.85
- Average True Range (ATR)
- CUE 0.05
- ICCM 0.04
- MACD
- CUE -0.01
- ICCM -0.01
- Stochastic Oscillator
- CUE 10.92
- ICCM 5.03
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.